Ordinary Reweighting | RBC Biotech Opportunities NTR Index | Effective Date 3rd October 2022

In the ordinary reweighting the following composition will be implemented effective open 03.10.2022:

ABBVIE INC
ALNYLAM PHARMACEUTICALS INC
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
ELI LILLY & CO
GILEAD SCIENCES INC
GLOBAL BLOOD THERAPEUTICS IN
INCYTE CORP
INTRA-CELLULAR THERAPIES INC
KARUNA THERAPEUTICS INC
SAREPTA THERAPEUTICS INC
SEAGEN INC